相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
Natalia Gonzalez Caldito et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases
Pierre Durozard et al.
ANNALS OF NEUROLOGY (2020)
MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity
Athanasios Papathanasiou et al.
JOURNAL OF NEUROLOGY (2020)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody
Romana Hoeftberger et al.
ACTA NEUROPATHOLOGICA (2020)
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2020)
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Yoshiki Takai et al.
BRAIN (2020)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Old and new breakthroughs in neuromyelitis optica
Hans-Peter Hartung et al.
LANCET NEUROLOGY (2020)
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland
Laura Airas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases
Simone Mader et al.
CURRENT OPINION IN NEUROLOGY (2020)
Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics
Kazuo Fujihara et al.
CURRENT OPINION IN NEUROLOGY (2020)
Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules
Benjamin P. Trewin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Serious safety events in rituximab-treated multiple sclerosis and related disorders
Brandi L. Vollmer et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study
Renata Barbosa Paolilo et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
Huah Shin Ng et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
Daniel H. Whittam et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica
John R. Ciotti et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Fulin Gao et al.
BMC NEUROLOGY (2019)
Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production
Elizabeth Cotzomi et al.
BRAIN (2019)
Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis
Laura Ambra Nicolini et al.
JAMA NEUROLOGY (2019)
A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder
Maureen A. Mealy et al.
MEDICINE (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders
Giovanni Novi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination
Xiaoyang Li et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Identification of circulating MOG-specific B cells in patients with MOG antibodies
Stephan Winklmeier et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Markus Reindl et al.
NATURE REVIEWS NEUROLOGY (2019)
Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder
Su-Hyun Kim et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
Maria R. Ciardi et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein
Melania Spadaro et al.
ANNALS OF NEUROLOGY (2018)
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
Philippe Cabre et al.
JOURNAL OF NEUROLOGY (2018)
Disease Course and Treatment Responses in Children With RelapsingMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Yael Hacohen et al.
JAMA NEUROLOGY (2018)
Monitoring CD27+memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study
M. Cohen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up
M. E. Evangelopoulos et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in inflammatory Demyelinating Diseases
Patrick Peschl et al.
FRONTIERS IN IMMUNOLOGY (2017)
Clinical presentation and prognosis in MOG-antibody disease: a UK study
Maciej Jurynczyk et al.
BRAIN (2017)
Rituximab does not reset defective early B cell tolerance checkpoints
Nicolas Chamberlain et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
Sandra Gallagher et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
Pietro Annovazzi et al.
JOURNAL OF NEUROLOGY (2016)
Disease-modifying therapies and infectious risks in multiple sclerosis
Alexander Winkelmann et al.
NATURE REVIEWS NEUROLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
Valentina Damato et al.
JAMA NEUROLOGY (2016)
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
Ding Chen et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
B lymphocytes in neuromyelitis optica
Jeffrey L. Bennett et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
CD19 as a molecular target in CNS autoimmunity
Olaf Stueve et al.
ACTA NEUROPATHOLOGICA (2014)
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Corinna Trebst et al.
JOURNAL OF NEUROLOGY (2014)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
Elizabeth Ward et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
Ronald Herbst et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
分享论文
